WINTON GROUP Ltd Makes New $1.08 Million Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

WINTON GROUP Ltd acquired a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,389 shares of the company’s stock, valued at approximately $1,084,000.

Other institutional investors also recently modified their holdings of the company. Montanaro Asset Management Ltd raised its position in TransMedics Group by 19.4% during the 4th quarter. Montanaro Asset Management Ltd now owns 140,035 shares of the company’s stock valued at $8,731,000 after purchasing an additional 22,800 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of TransMedics Group by 21,100.9% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 23,109 shares of the company’s stock valued at $1,597,000 after acquiring an additional 23,000 shares in the last quarter. Prudential Financial Inc. lifted its stake in TransMedics Group by 1,023.2% in the fourth quarter. Prudential Financial Inc. now owns 34,056 shares of the company’s stock worth $2,123,000 after acquiring an additional 31,024 shares during the period. Emerald Advisers LLC boosted its holdings in TransMedics Group by 146.3% in the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after acquiring an additional 220,804 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in TransMedics Group by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock valued at $226,700,000 after purchasing an additional 40,860 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a report on Wednesday. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Trading Down 2.6 %

TransMedics Group stock opened at $68.58 on Friday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business’s fifty day simple moving average is $69.11 and its two-hundred day simple moving average is $88.41. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 72.96 and a beta of 2.12.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.